
Telesis Bio Investor Relations Material
Latest events

Q2 2023
Telesis Bio

Q3 2024
7 Nov, 2024

Q2 2024
7 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Telesis Bio Inc
Access all reports
Telesis Bio Inc. is a synthetic biology company that provides automated solutions for DNA and RNA synthesis. Its core product, the BioXp system, is the world’s first fully automated gene synthesis platform, enabling researchers to rapidly design, build, and clone high-quality synthetic DNA and mRNA. Telesis Bio's technologies are widely used in various applications, including vaccine development, gene and cell therapy, precision medicine, and biologics drug discovery. Telesis Bio is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
DNAY
Country
🇺🇸 United States